Author Tries £325 NAD+ Injections, Then Quits After Hyperactivity and GI Problems
Updated
Updated · The Times · May 13
Author Tries £325 NAD+ Injections, Then Quits After Hyperactivity and GI Problems
1 articles · Updated · The Times · May 13
A 50mg NAD+ shot left the author feeling intensely hyperactive within two hours and sent her home with gastrointestinal distress, prompting her to throw away the £325 injector pen.
The self-experiment followed a £155 consultation with London clinic Nuutro and a broader push into peptides and injectables sold for energy, sleep, recovery and longevity.
Clinics and online sellers operate in a UK regulatory grey area: many compounds are not licensed medicines, and the MHRA is investigating clinics that market unapproved peptides with medical claims.
Doctors quoted in the report said anecdotal enthusiasm is outrunning evidence, warning that self-prescribing brings risks from contamination, dosing errors, drug interactions and limited long-term safety data.
The boom has been fueled by GLP-1 success, influencer marketing and distrust of mainstream medicine, turning once-obscure compounds such as BPC-157, retatrutide and melanotan II into grey-market wellness products.
Are the anti-aging benefits of self-injected peptides worth the unknown risks of cancer and other long-term side effects?
As the FDA moves to legalize peptides this July, are we entering a new era of medicine or a public health crisis?